Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Informācija par akcionāru sapulcēm |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2014-09-24 17:30:54 |
Versijas komentārs | |
Teksts |
Riga, 24 September 2014 The joint stock company “Grindeks” (Unified Reg. No. 40003034935, Legal address: 53 Krustpils St., Riga, LV - 1057, Latvia) announces that the shareholder “ABLV Private Equity Fund 2010”, KS (Unified Reg. No. 40103307758, Legal address: 23 Elizabetes St., Riga, LV – 1010, Latvia), which represents voting capital of joint stock company “Grindeks” in the total amount of 22.66%, has submitted following draft resolutions of items included in the agenda of joint stock company “Grindeks” Extraordinary General Meeting of shareholders to be held on 11 November 2014 at 11 a.m. at premises of joint stock company “Grindeks”, 53 Krustpils street, Riga, Latvia: A. To take the following decision on the first item
“Distribution of the profit for the year 2013”: B. To take the following decision on the
second item ”Election of the Supervisory Council” (in accordance
with the procedure established in the Commercial Law regarding
reelection of Supervisory Council): The shareholder “ABLV Private Equity Fund 2010”, KS has nominated Agris Grīnbergs (CV enclosed) as a candidate of the member of joint stock company “Grindeks” Supervisory Council. Draft Resolutions prepared by the Management Board of joint stock company “Grindeks” in accordance with the Article 273 part 5 of Commercial law will be published no later than fourteen days prior to the Extraordinary General Meeting to be held on 11 November 2014. About “Grindeks” “Grindeks” is the leading pharmaceutical company in the Baltic States. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. “Grindeks” Group consists of 4 subsidiary companies in Latvia, Estonia and Russia; representative offices are opened in 13 countries. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. The portfolio of “Grindeks” products consists of successful combination of branded products and generic medications – including brand products Mildronate® and Ftorafur®, as well as more than 100 effective and safe medications. Currently “Grindeks” manufactures 25 active pharmaceutical ingredients. Products of the company are exported to 59 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S. To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing 70.7 million euros over the years. JSC “Grindeks” shares are listed on the Official List of “NASDAQ OMX Riga”. Major shareholders of JSC “Grindeks” are Kirovs Lipmans – 33.29%, “AB.LV Private Equity fund 2010” – 22.66%, Anna Lipmane – 16.69%, “Swedbank” AS Clients Account (nominee account) – 10.47%. More information about the company
–
www.grindeks.lv/en/ Additional information: Laila Kļaviņa |
Pielikumi |